Efficiency and safety of inhaled amphotericin B lipid complex (Abelcet) in the prophylaxis of invasive fungal infections following lung transplantation.

[1]  M. Klepser,et al.  Safety of aerosolized amphotericin B , 2007, Expert opinion on drug safety.

[2]  A. Deykin,et al.  Safety of aerosolized liposomal versus deoxycholate amphotericin B formulations for prevention of invasive fungal infections following lung transplantation: a retrospective study , 2007, Transplant infectious disease : an official journal of the Transplantation Society.

[3]  J. Aguado,et al.  Incidence, Clinical Characteristics and Risk Factors of Late Infection in Solid Organ Transplant Recipients: Data from the RESITRA Study Group , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[4]  D. Pakstis,et al.  Voriconazole Prophylaxis in Lung Transplant Recipients , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[5]  S. Magill,et al.  Antifungal prophylaxis in transplant recipients: where do we go from here? , 2006, Transplant infectious disease : an official journal of the Transplantation Society.

[6]  D. Paterson,et al.  Aerosol Deposition of Lipid Complex Amphotericin‐B (Abelcet) in Lung Transplant Recipients , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[7]  R. Drew.  Potential role of aerosolized amphotericin B formulations in the prevention and adjunctive treatment of invasive fungal infections. , 2006, International journal of antimicrobial agents.

[8]  T. Walsh,et al.  Current approaches to diagnosis and treatment of invasive aspergillosis. , 2006, American journal of respiratory and critical care medicine.

[9]  P. Marik.  Fungal infections in solid organ transplantation , 2006, Expert opinion on pharmacotherapy.

[10]  A. Milstone,et al.  An overview of fungal prophylaxis in lung transplantation , 2005 .

[11]  A. Solé,et al.  Aspergillus infections in lung transplant recipients: risk factors and outcome. , 2005, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[12]  J. Gavaldà,et al.  Nebulized liposomal amphotericin B (n-LAB) prophylaxis for aspergillus infection in lung transplantation (LT): Pharmacokinetics, safety and efficacy , 2005 .

[13]  S. Crawford,et al.  Pulmonary complications of solid organ and hematopoietic stem cell transplantation. , 2004, American journal of respiratory and critical care medicine.

[14]  J. Perfect,et al.  Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients , 2004, Transplantation.

[15]  S. Aguade,et al.  Nebulized amphotericin B concentration and distribution in the respiratory tract of lungtransplanted patients , 2003, Transplantation.

[16]  Nina Singh,et al.  Aspergillus infections after lung transplantation: clinical differences in type of transplant and implications for management. , 2003, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[17]  I. Mellinghoff,et al.  Treatment of Scedosporium apiospermum brain abscesses with posaconazole. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  J. Perfect,et al.  SAFETY OF AEROSOLIZED AMPHOTERICIN B LIPID COMPLEX IN LUNG TRANSPLANT RECIPIENTS12 , 2001, Transplantation.

[19]  V. Calvo,et al.  Antifungal prophylaxis during the early postoperative period of lung transplantation. Valencia Lung Transplant Group. , 1999, Chest.

[20]  D. Armstrong,et al.  Efficacy of prophylactic aerosol amphotericin B lipid complex in a rat model of pulmonary aspergillosis , 1997, Antimicrobial agents and chemotherapy.

[21]  S. Hunt,et al.  Significant reduction in the number of fungal infections after lung-, heart-lung, and heart transplantation using aerosolized amphotericin B prophylaxis. , 1997, Transplantation proceedings.

[22]  N. Kohno,et al.  [Lipoid pneumonia combined with pulmonary nocardiosis caused by inhalation of amphotericin-B after renal transplantation]. , 1996, Nihon Kyobu Shikkan Gakkai zasshi.

[23]  J. Gryn,et al.  The Toxicity of Daily Inhaled Amphotericin B , 1993, American journal of clinical oncology.

[24]  D. Denning,et al.  Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  R. Proffitt,et al.  EFFICACY OF AEROSOLIZED LIPOSOMAL AMPHOTERICIN B (AMBISOME®) AS A PROPHOLACTIC TREATMENT IN AN IMMUNE COMPROMISED MURINE MODEL OF PULMONARY ASPERGILLOSIS , 1994 .